NCT06926933进行中（未招募）4 期
An Open Label, Single-group, Multicenter Study on the Efficacy and Safety of Leuprolide Acetate 45 mg for Injectable Suspension-controlled Release in Subjects With Central (Gonadotropin-dependent) Precocious Puberty
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
- 试验地点
- 10
- 主要终点
- The percentage (%) of subjects with serum LH concentrations < 4 IU/L following an GnRH stimulation test
研究概览
简要总结
This study is a multicenter, open-label, single-group, and phase 4 study to evaluate the efficacy and safety of 45 mg of leuprolide acetate in CPP.
Screening tests are performed after the subject agrees in writing to participate in the clinical trial, and subjects who meet the inclusion criteria and do not fall under the exclusion criteria are enrolled in the study. The target patients in this study are pediatric patients who have been diagnosed with CPP but have not yet received GnRH agonist treatment, and all subjects perform GnRH stimulation tests to confirm their CPP diagnosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 4 Years 至 9 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pubertal-type LH response following an abbreviated GnRH stimulation test before treatment initiation > 5 IU/L
- •A subject manifested with central precocious puberty according to the following criteria Age : Boy (4 years of age or older ~ under 9 years of age) Girl (4 years of age or older ~ under 8 years of age) Tanner Stage : Level 2 or higher
- •Based on baseline visit (Day 0), those under the age of 10 for boys and those under the age of 9 for girls
- •Confirmed diagnosis of CPP within 12 months of Baseline Visit (Day 0) but have not received prior GnRH agonist treatment for CPP
- •Children with a body weight of more than 20 kg at screening
- •Children have a bone age that is ≥1 year older than their chronological age at screening
- •A signed written consent form by a legal representative who has been informed about this study
排除标准
- •Gonadotropin-independent (peripheral) precocious puberty: extra pituitary secretion of gonadotropins or gonadotropin-independent gonadal or adrenal sex steroid secretion
- •Prior or current GnRH treatment for CPP
- •Non-progressing isolated premature thelarche
- •Presence of an unstable intracranial tumor or an intracranial tumor requiring neurosurgery or cerebral irradiation. Subjects with hamartomas not requiring surgery are eligible.
- •Prior (within 12 weeks of Screening) use of medications
- •Hormonal agonists (Estrogen, Progesterone, FSH, LH, Testosterone etc.)
- •Hormonal antagonists (Anti-Estrogen agents, Anti-Androgen agents)
- •Steroid use (except for mild topical steroids, oral steroids are allowed within 30 days)
- •Herbal Medicines
- •Prior or current therapy with growth hormone
- •Major medical or psychiatric illness that could interfere with study visits
- •Diagnosis of short stature (i.e. 2 standard deviations (SD) below the mean height for age or 3rd percentile for age)
- •Pregnant or likely pregnant women (Positive urine pregnancy test), nursing women
- •Known hypersensitivity to GnRH or related compounds
- •Any other medical condition or serious intercurrent illness that, in the opinion of the investigator, may make it undesirable for the subject to participate in the study
- •Any other condition(s) which could significantly interfere with Protocol compliance
- •Treatment with an investigational product within 5 half-lives of that product in prior clinical studies before the baseline visit (Day 0)
- •Known history of seizures, epilepsy, and/or central nervous system disorders that may be associated with seizures or convulsions
- •Prior (within 6 months of Baseline (Day 0)) or current use of medications that, per investigator opinion, have been associated with seizures or convulsions
研究组 & 干预措施
Eligard® 45 mg
Experimental
SC injection of study drug (45 mg of leuprolide acetate for injectable suspensions)
干预措施: Eligard® 45 mg (Drug)
结局指标
主要结局
The percentage (%) of subjects with serum LH concentrations < 4 IU/L following an GnRH stimulation test
时间窗: at week 24
Blood samples for serum LH concentrations (as appropriate) will be collected at the appropriate assessment times and analyzed by a central laboratory.
次要结局
- The percentage (%) of subjects with suppressed serum FSH (< 2.5 mIU/mL), estradiol (< 20 pg/mL, for girl) or testosterone (< 30 ng/dL, for boy)(at week 12, 24, 48, 72, 96)
- The percentage of subject of Tanner stage (including menstruation)(at week 12, 24, 48, 72, 96)
- Height velocity (growth rate)(at week 12, 24, 48, 72, 96)
- The ratio of bone age and chronological age(at week 12, 24, 48, 72, 96)
- The percentage (%) of subjects with suppressed serum LH concentrations (< 4 IU/L) 30-minutes post GnRH stimulation test(at week 12, 48, 72, 96)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
不适用
Correlation Study Between PEST and SCORAD in Management of Atopic Dermatitis With Ceradan® RegimenAtopic DermatitisNCT02073591Hyphens Pharma Pte Ltd58
已完成
4 期
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)Juvenile Idiopathic ArthritisNCT03301883Hoffmann-La Roche62
招募中
4 期
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene TherapyMuscular Atrophy, SpinalNCT05861999Hoffmann-La Roche28
招募中
4 期
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene TherapyMuscular Atrophy, SpinalNCT05861986Hoffmann-La Roche28
已完成
4 期
MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb SpasticitySpasticity, MuscleNCT03908580Medy-Tox120